Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Susan Halabi

Showing results (91-100 of 282) with videos related to

Pageof 29
Sort By:
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 28, 2015
Refining Prognosis in Lung Cancer: A Report on the Quality and Relevance of Clinical Prognostic ToolsAlyson L Mahar, Carolyn Compton, Lisa M McShane, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 3, 2019
Reply to L. Dirix, B. De Laere et al, and A. Sharp et alAndrew J Armstrong, Susan Halabi, Jun Luo, et al.
Environmental Geochemistry and Health|December 4, 2014
Mercury hair levels and factors that influence exposure for residents of Huancavelica, PeruNicole Hagan, Nicholas Robins, Heileen Hsu-Kim, et al.
Cancer|February 22, 2002
Higher doses of mitoxantrone among men with hormone-refractory prostate carcinoma: a Cancer and Leukemia Group B studyEllis G Levine, Susan Halabi, John D Roberts, et al.
Annals of Surgical Oncology|April 8, 2016
Critical Assessment of Clinical Prognostic Tools in MelanomaAlyson L Mahar, Carolyn Compton, Susan Halabi, et al.
Cancer|August 16, 2006
A phase II study of gemcitabine and capecitabine in metastatic renal cancer: a report of Cancer and Leukemia Group B protocol 90008Walter M Stadler, Susan Halabi, Brian Rini, et al.
Cancer|December 12, 2003
A phase II study of estramustine, docetaxel, and carboplatin with granulocyte-colony-stimulating factor support in patients with hormone-refractory prostate carcinoma: Cancer and Leukemia Group B 99813William K Oh, Susan Halabi, W Kevin Kelly, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 10, 2005
The prognostic significance of plasma interleukin-6 levels in patients with metastatic hormone-refractory prostate cancer: results from cancer and leukemia group B 9480Daniel J George, Susan Halabi, Timothy F Shepard, et al.
Cancer|April 27, 2012
Combination external beam radiation and brachytherapy boost with androgen deprivation for treatment of intermediate-risk prostate cancer: long-term results of CALGB 99809Mark D Hurwitz, Susan Halabi, Laura Archer, et al.
Clinical Genitourinary Cancer|April 11, 2020
Androgens and Overall Survival in Patients With Metastatic Castration-resistant Prostate Cancer Treated With DocetaxelCharles J Ryan, Sandipan Dutta, William K Kelly, et al.
Pageof 29

Showing results (91-100 of 282) with videos related to

Sort By:
Pageof 29
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 28, 2015
Refining Prognosis in Lung Cancer: A Report on the Quality and Relevance of Clinical Prognostic ToolsAlyson L Mahar, Carolyn Compton, Lisa M McShane, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 3, 2019
Reply to L. Dirix, B. De Laere et al, and A. Sharp et alAndrew J Armstrong, Susan Halabi, Jun Luo, et al.
Environmental Geochemistry and Health|December 4, 2014
Mercury hair levels and factors that influence exposure for residents of Huancavelica, PeruNicole Hagan, Nicholas Robins, Heileen Hsu-Kim, et al.
Cancer|February 22, 2002
Higher doses of mitoxantrone among men with hormone-refractory prostate carcinoma: a Cancer and Leukemia Group B studyEllis G Levine, Susan Halabi, John D Roberts, et al.
Annals of Surgical Oncology|April 8, 2016
Critical Assessment of Clinical Prognostic Tools in MelanomaAlyson L Mahar, Carolyn Compton, Susan Halabi, et al.
Cancer|August 16, 2006
A phase II study of gemcitabine and capecitabine in metastatic renal cancer: a report of Cancer and Leukemia Group B protocol 90008Walter M Stadler, Susan Halabi, Brian Rini, et al.
Cancer|December 12, 2003
A phase II study of estramustine, docetaxel, and carboplatin with granulocyte-colony-stimulating factor support in patients with hormone-refractory prostate carcinoma: Cancer and Leukemia Group B 99813William K Oh, Susan Halabi, W Kevin Kelly, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 10, 2005
The prognostic significance of plasma interleukin-6 levels in patients with metastatic hormone-refractory prostate cancer: results from cancer and leukemia group B 9480Daniel J George, Susan Halabi, Timothy F Shepard, et al.
Cancer|April 27, 2012
Combination external beam radiation and brachytherapy boost with androgen deprivation for treatment of intermediate-risk prostate cancer: long-term results of CALGB 99809Mark D Hurwitz, Susan Halabi, Laura Archer, et al.
Clinical Genitourinary Cancer|April 11, 2020
Androgens and Overall Survival in Patients With Metastatic Castration-resistant Prostate Cancer Treated With DocetaxelCharles J Ryan, Sandipan Dutta, William K Kelly, et al.
Pageof 29